GSK selects Witty as next CEO

Share this article:

GlaxoSmithKline (GSK) has tapped Englishman Andrew Witty to succeed Jean Pierre Garnier as CEO in May.

At age 43, Witty will become the youngest–ever leader of Europe's largest drug maker at a time when the company is seeking to reinvigorate its sales growth.

Witty has worked for the UK-based GSK in the US, Asia and Africa and became president of European operations in 2003.

Witty joined GSK in 1985 in the UK where he held positions as director of pharmacy and distribution and international product manager.

Outside the UK, he was director for south and east Africa and marketing manager for GSK's US unit before moving to Singapore as an Asian SVP.

Garnier, who turns 60 at the end of October, joined SmithKline Beecham in 1990 as president of its North American pharmaceuticals division. He was named CEO in 2000.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.